IP Library Granted Patent US 8,722,341
Granted Patent B2
US 8,722,341 · App. 12/319,152 · Granted May 13, 2014

Metapneumovirus strains and their use in vaccine formulations and sequences

Inventors: Ronaldus Adrianus Maria Fouchier (Rotterdam, NL); Bernadetta Gerarda Van Den Hoogen (Rotterdam, NL); Albertus Dominicus Marcellinus Erasmus Osterhaus (Bunnik, NL); Aurelia Haller (Redwood City, CA); Roderick Tang (San Carlos, CA)
Assignees: ViroNovative B.V.; MedImmune Vaccines, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,341
App. No.
12/319,152
Granted
May 13, 2014
Kind
B2
Abstract

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV). Described are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. Also described is mammalian MPV, subgroups and variants thereof, and genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods is provided. Nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus are described. Also provided are chimeric or recombinant viruses encoded by said nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.

Claims (6)

1. An isolated antibody, wherein the antibody binds specifically to a protein consisting of the amino acid sequence of SEQ ID NO:366.

2. A method of detecting a mammalian metapneumovirus in a sample, wherein the method comprises contacting the sample with the antibody of claim 1 .

3. The antibody of claim 1 , wherein the antibody is a polyclonal antibody, a monoclonal antibody, a multispecific antibody, a human antibody, a humanized antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab′) fragment, a fragment produced by a Fab expression library, an anti-idiotypic (anti-Id) antibody, or an epitope-binding fragment.

4. The antibody of claim 1 , wherein the antibody is a human antibody or a humanized antibody.

5. A kit for the detection of MPV, comprising in one or more containers an antibody of claim 1 , 3 or 4 .

6. The kit of claim 5 , further comprising means to detect the antibody.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2016
From: VIRONOVATIVE B.V.
To: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
Reel/Frame 037726/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2015
From: MEDIMMUNE LLC; MEDIMMUNE VACCINES, INC.
To: VIRONOVATIVE, BV
Reel/Frame 035269/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2014
From: HALLER, AURELIA; TANG, RODERICK
To: MEDIMMUNE VACCINES, INC.
Reel/Frame 032136/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2014
From: FOUCHIER, RONALDUS ADRIANUS MARIA; VAN DEN HOOGEN, BERNADETTA GERARDA; OSTERHAUS, ALBERTUS DOMINICUS MARCELLINUS ERASMUS
To: VIRONOVATIVE BV
Reel/Frame 032136/0801 →
Priority Claims (2)
EP 01200213 · Jan 19, 2001 · regional
EP 01203985 · Oct 18, 2001 · regional
Continuity (4)
Continuation 10371122 · Feb 21, 2003
Continuation In Part PCTNL0200040 · Jan 18, 2002
Provisional Application 60358934 · Feb 21, 2002
Related Publication 20100143407A1 · Jun 10, 2010